首页>
外国专利>
RIFABUTIN FOR THE TREATMENT OF ACINETOBACTER BAUMANNII
RIFABUTIN FOR THE TREATMENT OF ACINETOBACTER BAUMANNII
展开▼
机译:RIFABUTIN用于治疗鲍曼不动杆菌
展开▼
页面导航
摘要
著录项
相似文献
摘要
To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 μg/ml and 4 μg/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.
展开▼